Noramco, a prominent worldwide producer of active pharmaceutical ingredients (APIs), renowned for its proficiency in controlled substances, has successfully concluded the acquisition of the Cambrex Drug Product Business Unit, previously recognized as Halo Pharmaceuticals. This acquisition broadens Noramco's offerings for API clientele, including those of its subsidiary, Purisys. The expanded services now encompass drug product formulation development, along with clinical and commercial drug product manufacturing and packaging, all accessible from facilities situated in Mirabel, Québec, and Whippany, New Jersey. As part of this acquisition, Noramco is reintroducing the Halo Pharmaceutical brand.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!